Mayne Pharma Group Limited (HG6.F)

4.1800 -0.0400 (-0.95%) At close: 08:03AM CEST

Mayne Pharma Group Limited

1538 Main North Road
Salisbury South, SA 5106
Australia
61 8 8209 2666
https://www.maynepharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Shawn Patrick O'Brien B.Sc	CEO, MD & Director	771.21k	N/A	1959
Mr. Aaron Gray	Chief Financial Officer	646.93k	N/A	N/A
Ms. Kimberly Parker J.D.	Executive VP & General Counsel	N/A	N/A	N/A
Mr. Brant Schofield	Executive Vice President of Corporate Development	630.85k	N/A	1966
Ms. Erinn Nathaniel	Director of Global Human Resources	N/A	N/A	N/A
Mr. Daniel Moore	Executive Vice President of Commercial	N/A	N/A	N/A
Dr. Frank Casty M.D.	Executive VP & Global Chief Medical Officer	N/A	N/A	N/A
Mr. Brenton Walter	Financial Controller	N/A	N/A	N/A
Ms. Laura Loftus	Associate General Counsel & Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Corporate governance

Mayne Pharma Group Limited’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 5; Board: 3; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.